5-substituted-2-phenylamino-benzamid es as MEK inhibitors

Details for Australian Patent Application No. 2005265769 (hide)

Owner Chugai Seiyaku Kabushiki Kaisha

Inventors Mizuguchi, Eisaku; Aida, Satoshi; Tsujii, Shinji; Kohchi, Yasunori; Kohchi, Masami; Shimma, Nobuo; Isshiki, Yoshiaki; Murata, Takeshi; Iikura, Hitoshi; Miwa, Masanori; Aso, Kosuke; Matsubara, Yasuaki

Agent Spruson & Ferguson

Pub. Number AU-B-2005265769

PCT Pub. Number WO2006/011466

Priority 2005-072093 14.03.05 JP; 2004-218004 26.07.04 JP

Filing date 26 July 2005

Wipo publication date 2 February 2006

Acceptance publication date 16 December 2010

International Classifications

C07C 259/10 (2006.01) Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups

A61K 31/166 (2006.01) - having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol

A61K 31/4015 (2006.01) - having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide

A61K 31/4164 (2006.01) - 1,3-Diazoles

A61K 31/42 (2006.01) - Oxazoles

A61K 31/421 (2006.01) - 1,3-Oxazoles, e.g. pemoline, trimethadione

A61K 31/45 (2006.01) - having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide

A61K 31/505 (2006.01) - Pyrimidines

A61K 31/535 (2006.01) - having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines

A61K 31/5375 (2006.01) - 1,4-Oxazines, e.g. morpholine

A61K 31/539 (2006.01) - having two or more oxygen atoms in the same ring, e.g dioxazines

A61P 1/16 (2006.01) Drugs for disorders of the alimentary tract or the digestive system

A61P 3/10 (2006.01) Drugs for disorders of the metabolism

A61P 9/00 (2006.01) Drugs for disorders of the cardiovascular system

A61P 9/04 (2006.01) Drugs for disorders of the cardiovascular system

A61P 9/10 (2006.01) Drugs for disorders of the cardiovascular system

A61P 11/00 (2006.01) Drugs for disorders of the respiratory system

A61P 11/06 (2006.01) Drugs for disorders of the respiratory system

A61P 17/06 (2006.01) Drugs for dermatological disorders

A61P 19/02 (2006.01) Drugs for skeletal disorders

A61P 25/28 (2006.01) Drugs for disorders of the nervous system

A61P 29/00 (2006.01) Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents

A61P 31/04 (2006.01) Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

A61P 31/18 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Event Publications

15 March 2007 PCT application entered the National Phase

  PCT publication WO2006/011466 Priority application(s): WO2006/011466

26 April 2007 Amendment Made

  The nature of the amendment is: Amend the invention title to read 5-substituted-2-phenylamino-benzamides as MEK inhibitors

16 December 2010 Application Accepted

  Published as AU-B-2005265769

14 April 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005265772-Novel cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes

2005265715-Novel glucitol derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes